Your browser is no longer supported. Please, upgrade your browser.
GNCA Genocea Biosciences, Inc. weekly Stock Chart
GNCA [NASD]
Genocea Biosciences, Inc.
Index- P/E- EPS (ttm)-1.50 Insider Own0.20% Shs Outstand28.14M Perf Week-7.76%
Market Cap55.81M Forward P/E- EPS next Y-1.52 Insider Trans0.00% Shs Float24.04M Perf Month-21.40%
Income-36.20M PEG- EPS next Q-0.41 Inst Own51.80% Short Float0.37% Perf Quarter10.99%
Sales- P/S- EPS this Y30.00% Inst Trans-5.44% Short Ratio0.22 Perf Half Y-16.18%
Book/sh0.44 P/B4.59 EPS next Y5.00% ROA-63.60% Target Price- Perf Year-47.67%
Cash/sh0.96 P/C2.11 EPS next 5Y- ROE-138.00% 52W Range1.10 - 3.94 Perf YTD-2.42%
Dividend- P/FCF- EPS past 5Y36.40% ROI- 52W High-52.25% Beta2.33
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low70.94% ATR0.20
Employees59 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)33.39 Volatility6.74% 9.13%
OptionableYes Debt/Eq1.11 EPS Q/Q62.70% Profit Margin- Rel Volume1.34 Prev Close2.02
ShortableYes LT Debt/Eq0.47 EarningsApr 30 BMO Payout- Avg Volume396.62K Price1.88
Recom1.40 SMA20-16.38% SMA50-22.48% SMA200-16.55% Volume468,605 Change-6.92%
Nov-15-19Initiated SVB Leerink Outperform $7
Jul-08-19Resumed Stifel Buy $13
Mar-01-19Reiterated Needham Buy
Feb-06-18Upgrade Needham Hold → Buy $3
Sep-27-17Downgrade Needham Buy → Hold
Sep-26-17Downgrade Stifel Buy → Hold $15 → $2.50
Jul-25-17Upgrade Needham Hold → Buy $12
Feb-17-17Downgrade Needham Buy → Hold
Apr-01-16Reiterated Stifel Buy $11 → $13
Dec-17-15Initiated UBS Buy $15
Oct-20-15Reiterated Needham Buy $22 → $15
Oct-19-15Reiterated FBR Capital Outperform $20 → $17
Mar-05-14Initiated Needham Buy $22
Mar-03-14Initiated Stifel Buy $25
Jul-06-20 09:27AM  
Jun-23-20 03:52PM  
Jun-22-20 09:00AM  
Jun-15-20 07:30AM  
May-29-20 08:00AM  
May-19-20 07:30AM  
May-13-20 06:02PM  
07:40AM  
May-12-20 05:32PM  
May-11-20 04:30PM  
May-05-20 04:05PM  
Apr-30-20 07:00AM  
Apr-24-20 06:11AM  
Apr-23-20 08:01PM  
11:44AM  
Apr-21-20 07:00AM  
Apr-08-20 04:01PM  
Feb-26-20 04:05PM  
Feb-20-20 09:15PM  
08:00AM  
Feb-13-20 07:00AM  
Feb-06-20 07:30AM  
Dec-14-19 09:43PM  
Nov-14-19 05:00PM  
08:30AM  
Nov-09-19 09:00AM  
Nov-05-19 08:05AM  
Oct-29-19 07:22AM  
Oct-24-19 07:00AM  
Oct-17-19 08:00AM  
Sep-30-19 01:13PM  
Sep-27-19 08:00AM  
Sep-18-19 09:31AM  
Aug-30-19 08:00AM  
Aug-24-19 01:46PM  
Aug-05-19 01:13PM  
Jul-25-19 07:00AM  
Jul-18-19 08:00AM  
Jun-25-19 08:37AM  
Jun-24-19 01:58PM  
Jun-20-19 09:52AM  
Jun-18-19 04:04PM  
Jun-03-19 12:47PM  
10:45AM  
09:17AM  
07:00AM  
May-31-19 12:44PM  
08:00AM  
May-23-19 05:34PM  
May-16-19 01:00PM  
08:00AM  
Apr-30-19 08:13AM  
08:00AM  
Apr-23-19 08:00AM  
Apr-03-19 04:01PM  
Apr-02-19 01:00PM  
Mar-20-19 10:38AM  
Mar-19-19 11:52AM  
Mar-13-19 08:23AM  
Mar-07-19 08:18AM  
Mar-06-19 08:05AM  
Feb-28-19 08:00AM  
Feb-21-19 08:00AM  
Feb-12-19 08:30AM  
Jan-30-19 02:21PM  
Jan-02-19 11:55AM  
08:00AM  
Dec-14-18 12:14PM  
Dec-10-18 08:00AM  
Nov-27-18 08:40AM  
Nov-15-18 08:00AM  
Nov-06-18 07:10PM  
08:00AM  
Nov-01-18 08:35AM  
08:00AM  
Oct-25-18 08:05AM  
Oct-19-18 03:07PM  
Oct-11-18 08:35AM  
Oct-09-18 08:35AM  
Oct-01-18 07:30AM  
Sep-24-18 08:02AM  
Aug-29-18 08:05AM  
Aug-16-18 05:41AM  
Aug-07-18 07:35AM  
Aug-02-18 03:18PM  
09:58AM  
08:04AM  
07:00AM  
Jul-26-18 08:05AM  
Jul-11-18 07:35AM  
Jun-01-18 08:04AM  
May-10-18 09:02AM  
07:59AM  
May-04-18 08:04AM  
May-02-18 07:45AM  
Apr-30-18 08:04AM  
Apr-18-18 09:01AM  
Apr-09-18 08:05AM  
Mar-27-18 05:23AM  
Mar-12-18 05:39PM  
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.